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Infection with human papillomavirus (HPV) has been implicated
in more than 90% of cervical carcinomas in which specific viral
oncogenes have been shown to integrate into the host genome and
thereby deregulate cell proliferation. One such oncogene, E6,
interferes with proper cell growth regulation by promoting the
degradation of the tumour suppressor gene product P53 (zur
Hausen, 1996). A recent report by Storey et al (1998) presented
data suggesting that homozygosity for the allele encoding arginine
at the polymorphic codon 72 of P53 correlated with increased risk
of HPV-associated cervical cancer. These results were obtained
from genotyping 30 cervical tumours and 41 normal controls, with
an observed Arg/Arg frequency of 76% in cancer patients
compared to a frequency of 37% in controls. In addition, the data
were supported by results from an in vitro assay demonstrating
that the p53Arg form of the protein was more susceptible to degra-
dation by the HPV E6 oncoprotein than the p53Pro variant.
HPV infection has also been correlated with oral cancer develop-
ment. The overall prevalence of HPV in head and neck tumours is
estimated to range between 18.5% and 35.9% (McKaig et al, 1998)
depending on detection methods. The HPV types most frequently
associated with head and neck cancer are the same as those
primarily found in cervical cancer (i.e. HPV16 and HPV18). The
existence of a similar risk factor for a given P53 genotype in HPV-
related oral cancer would facilitate screening of HPV-infected indi-
viduals by focusing screening efforts on high-risk individuals. We
therefore examined the importance of this P53 polymorphism with
respect to the risk of cancer development in patients with squamous
cell carcinoma of the head and neck (SCCHN).
MATERIALS AND METHODS
Patients and controls examined in this study were interviewed
between 1994 and 1998 and were matched on the basis of similar
ethnic origin to control for population variations in allele frequen-
cies. A questionnaire recording lifetime tobacco exposure was
completed by all participants. DNA was extracted from blood
using standard methods. Polymerase chain reaction (PCR) ampli-
fication was performed using standard buffer, nucleotides and
enzyme supplied by Pharmacia Biotech (Upsala, Sweden) and the
following primers: 4L1, 5¢-GCAACTGACCGTGCAAGTCA-3¢;
4U1, 5¢-ATCTACAGTCCCCCTTGCCG-3¢ (Sheldon Biotechnology
Center, Montreal, Quebec, Canada). Cycling was performed as
follows: 3 min denaturing at 95°C; 35 cycles of 30 s denaturation
at 95°C, 30 s annealing at 60°C, 30 s extension at 72°C; 10 min
incubation at 72°C. Restriction digestion with BstU1 was
performed using half the PCR reaction and according to the manu-
facturer’s instructions (New England Biolabs Inc., Beverly, MA,
USA). Digested samples were separated on 1.8% agarose-TBE
(Tris–borate EDTA) gels, stained with ethidium bromide and
photographed under UV. Statistical analysis was performed using
Arcus QuickStat (Biomedical). We used either the R ´ C c2 test for
association or Fisher’s exact test to analyse our data. Gart’s
method was used to construct exact confidence limits for the odds
ratio of the fourfold tables. With unmatched study design and a
sample size of 163 cases, matched 1:1 to controls with a = 0.05,
we have an 80% power to detect an odds ratio (OR) of 2.0 or
greater for the development of SCCHN in association with the
Arg/Arg genotype. The OR observed by Storey et al (1998) was
5.7. All P-values are 2-sided.
Results
We genotyped 163 incident and prevalent cases of SCCHN and
163 ethnically matched healthy controls. Cancer sites included the
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pharynx (n = 24), the nasal cavity (n = 4) and the larynx (n = 66).
The arginine form of codon 72 contains a BstU1 site that is not
present in the proline allele. We digested a 380-bp PCR fragment
amplified from leuckocyte DNA with the enzyme BstU1 and sepa-
rated the fragments by agarose gel electrophoresis. The arginine
allele, when cleaved by the BstU1 enzyme, yielded two fragments
of 210 and 170 bp, while the proline allele remained as a 380-bp
band on the gel. No difference between genotypic frequencies 
in SCCHN cases and controls was observed (R ´ C c2 = 0.64; 
P = 0.72) (Table 1). We then combined Pro/Pro homozygotes with
Arg/Pro heterozygotes and the data was further analysed by
Fisher’s exact test to determine whether cases showed a significant
excess of Arg/Arg homozygotes compared to controls, as was
reported previously, but no significant difference was observed 
(P = 0.50).
The purpose of ethnically matching controls to cases is to
prevent possible differences in allelic frequencies among various
ethnic groups from resulting in biased genotypic distributions. In
order to determine whether such ethnic differences exist for this
polymorphism, we examined genotypic frequencies in our control
group with respect to ethnic background using the R ´ C  c2
method. We found no significant difference in the genotypic distri-
butions of the various ethnic groups (c2 = 6.61; P = 0.36) (Table
2).
Differences in HPV positivity between cases and controls and
by head and neck cancer site could hide a genotypic bias in HPV-
infected patients, since about 18–36% of cases are expected to be
positive for HPV, depending on the techniques used (McKaig et al,
1998). We do not have HPV typing information for cases or
controls. Interestingly, both a positive (Schwartz et al, 1998) and
an inverse (Portugal et al, 1997) correlation between heavy
smoking (the most significant risk factor for SCCHN develop-
ment) and the presence of HPV in host DNA has been reported.
Schwartz et al (1998) also found that the oropharynx and the
tonsils were the head and neck sites most likely to harbour HPV.
This concurs with other data (McKaig et al, 1998). In light of these
results, we analysed our data in two ways. We first divided our
cases into four quartiles based on their pack year values. There
was no significant difference in genotypic frequency between
cases with these four different levels of tobacco exposure (c2 =
6.91;  P = 0.33) (Table 3). We also compared the genotypic
frequencies of the groups with the lowest and highest exposure
levels between which, based on previous results (Portugal et al,
1997; Schwartz et al, 1998), the greatest variation in the propor-
tion of HPV-related cancers should be observed. We saw no signif-
icant difference in the frequency of arginine homozygotes in cases
with the lowest and highest pack year values (P = 0.18, Table 3).
There was slight evidence for a linear trend towards the proline
allele being over-represented in cases with heavy tobacco
exposure, but 4/12 cells have an expected n < 5. When we
dichotomized the data at the median pack-year exposure for
controls as well as cases, there was no difference in the OR
between the lowest and highest exposed groups (1.19 and 1.09
respectively (non-significant), P = 0.85 for a test that the data are
derived from different populations, data not shown). It should be
noted that compared with the control group, the Arg/Arg allele
frequency (the presumed disease-associated genotype) was not
significantly elevated in any subgroup of SCCHN.
We then examined polymorphic frequencies by cancer sites.
Although there are great discrepancies from one study to another,
overall levels of HPV infection appear to be twice as high in
cancers of the oral cavity as they are in the larynx (Franceschi 
et al, 1996; McKaig et al, 1998) (in contrast to the situation with
laryngeal papillomatosis). Therefore we analysed the data without
the larynx cancer cases (n = 97). The results were similar to those
observed when the larynx cancer cases were included, and no
differences in genotype frequencies were observed (c2, P = 0.54,
data not shown). When we analysed oropharynx and tonsillar
cancers separately, no differences in genotype frequencies were
observed (Arg/Arg = 8 and Arg/Pro = 6), with this small sample
size (n = 14) we had very limited power to detect significant differ-
ences.
DISCUSSION
We report here P53 codon 72 polymorphism frequencies in
SCCHN. We did not observe a significant difference between
SCCHN cases and ethnically matched controls, nor did we find
varying genotypic frequencies among any subgroup of cases.
Following the earlier report (Storey et al, 1998), other studies of
cervical cancer cases which ascertained larger groups of cases and
controls have failed to uncover any significant overrepresentation
of the Arg heterozygous genotype in controls (Helland et al, 1998;
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Table 1 R72P P53 polymorphism genotype distribution in ethnically
matched cases and controls
Arg/Arg (%) Arg /Pro (%) Pro/Pro (%) Total (%)
Cases 88 (54.0) 68 (41.7) 7 (4.3) 163 (100)
Controls 95 (58.3) 61 (37.4) 7 (4.3) 163 (100)
R ´ C c2 = 0.64; P = 0.72. Fisher’s exact test (Pro/Pro and Arg/Pro
combined): P = 0.50 (OR = 0.84, 95% CI 0.75–1.89).
Table 2 Genotypic frequency in control individuals from differing ethnic
backgrounds
Ethnicity/ Arg/Arg (%) Arg/Pro (%) Pro/Pro (%) Total (%)
Country of origin
British 24 (63.2) 14 (36.8) 0 (0.0) 38 (100.0)
French Canadian 37 (54.4) 25 (36.8) 6 (8.8) 68 (100.0)
Jewish 18 (60.0) 12 (40.0) 0 (0.0) 30 (100.0)
Others 16 (59.3) 10 (37.0) 1 (3.7) 27 (100.0)
R ´ C c2 = 6.60; P = 0.36.
Table 3 Effect of tobacco exposure level on genotypic distribution in cases
Pack years Arg/Arg (%) Arg/Pro (%) Pro/Pro (%) Total (%)
0.0–18.9 24 (58.5) 17 (41.5) 0 (0.0) 41 (100.0)
19.0–39.0 24 (58.5) 16 (39.1) 1 (2.4) 41 (100.0)
40.0–60.8 23 (57.5) 14 (35.0) 3 (7.5) 40 (100.0)
61.0–153.7 17 (41.5) 21 (51.2) 3 (7.3) 41 (100.0)
R ´ C c2 = 6.91; P = 0.33. There is a linear trend of borderline significance 
(P = 0.057). Dichotomizing at the median pack-year exposure of cases
diminished the significance of this result (P = 0.12). R ´ C c2 (Pro/Pro and
Arg/Pro combined to test for excess Arg/Arg) = 3.47; P = 0.32. Fisher’s exact
test comparing lowest and highest quartiles (Pro/Pro and Arg/Pro combined):
P = 0.18 (OR = 1.99, 95% CI 0.76–5.27).Hildesheim et al, 1998; Josefsson et al, 1998; Minaguchi et al,
1998). In addition, in a follow-up study originally designed to
confirm the results presented by Storey et al (1998), genotyping of
a larger group of controls and of additional cervical cancer cases
(pooled with those cases previously reported) did not support the
original observation, mainly due to a dramatic change in allelic
frequencies in the control group. A genotypic distribution similar
to ours was found in both cases and controls (Arg/Arg = 54%,
Arg/Pro = 40%, Pro/Pro = 6% in cases; 63% Arg/Arg, 31%
Arg/Pro, 6% Pro/Pro in controls) (Rosenthal et al, 1998). This is
clear evidence that using controls derived from the same popula-
tion as the cases and adequate sizing of the control group are of
crucial importance to the validity of genotyping studies. Moreover,
it is uncertain which is the best technique to use to detect clinically
significant HPV infection of the head and neck (McKaig et al,
1998). Detection of HPV DNA in tumour tissue, which is the
approach used in most studies to determine HPV infection status,
may not be the best way to record on-going and persistent infec-
tion (Schwartz et al, 1998). The relationship between the codon 
72 polymorphism in P53 and HPV-positive SCCHN will not be
finally determined until the genotype at codon 72 is correlated
with the expression status of HPV in cases and controls, at each
SCCHN site. Nevertheless, our preliminary results suggest it is
unlikely that the Arg/Arg genotype of the P53 codon 72 poly-
morphism constitutes an increased risk factor in HPV-associated
SCCHN.
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